X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4470) 4470
Book Review (1411) 1411
Publication (615) 615
Book Chapter (38) 38
Conference Proceeding (24) 24
Government Document (3) 3
Dissertation (2) 2
Newspaper Article (2) 2
Streaming Video (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3497) 3497
humans (2489) 2489
immunotherapy (1853) 1853
animals (1681) 1681
immunology (1592) 1592
oncology (1509) 1509
ctla-4 (1413) 1413
cancer (1305) 1305
mice (1077) 1077
melanoma (1057) 1057
ctla-4 antigen (1028) 1028
ctla-4 blockade (1010) 1010
female (1010) 1010
male (910) 910
ipilimumab (907) 907
t cells (840) 840
lymphocytes (781) 781
ctla-4 protein (730) 730
metastatic melanoma (690) 690
antibodies, monoclonal - therapeutic use (670) 670
lymphocytes t (636) 636
pd-1 (617) 617
tumors (610) 610
expression (606) 606
care and treatment (579) 579
antigens (570) 570
t-lymphocytes - immunology (558) 558
ctla-4 antigen - immunology (551) 551
antigens, cd (548) 548
blockade (540) 540
abatacept (536) 536
ctla-4 antigen - antagonists & inhibitors (536) 536
middle aged (522) 522
immune checkpoint (500) 500
immunotherapy - methods (473) 473
t-cells (473) 473
dendritic cells (466) 466
research (459) 459
regulatory t-cells (451) 451
adult (442) 442
neoplasms - immunology (438) 438
immunoconjugates (428) 428
activation (427) 427
cytotoxicity (417) 417
medicine, research & experimental (410) 410
mice, inbred c57bl (410) 410
article (409) 409
aged (396) 396
pd-1 blockade (389) 389
in-vivo (388) 388
nivolumab (379) 379
melanoma - drug therapy (370) 370
analysis (366) 366
metastasis (366) 366
abridged index medicus (355) 355
programmed cell death 1 receptor - antagonists & inhibitors (353) 353
immune response (352) 352
chemical and pharmacologic phenomena (348) 348
health aspects (340) 340
therapy (338) 338
antitumor immunity (336) 336
apoptosis (336) 336
autoimmunity (336) 336
antineoplastic agents - therapeutic use (335) 335
antigens, differentiation - immunology (333) 333
mice, inbred balb c (333) 333
patients (333) 333
chemotherapy (331) 331
cell biology (323) 323
antigens, cd - immunology (322) 322
neoplasms - therapy (320) 320
t-lymphocytes, regulatory - immunology (319) 319
t cell receptors (314) 314
pd-1 protein (312) 312
lymphocyte activation (303) 303
treatment outcome (298) 298
melanoma - immunology (297) 297
cd28 (294) 294
immune system (293) 293
transplantation (291) 291
survival (288) 288
antibodies (282) 282
clinical trials (281) 281
cytokines (280) 280
gene expression (275) 275
monoclonal antibodies (274) 274
pd-l1 (269) 269
ctla-4 antigen - metabolism (268) 268
programmed cell death 1 receptor - immunology (267) 267
cd8-positive t-lymphocytes - immunology (263) 263
cancer therapies (262) 262
multidisciplinary sciences (261) 261
responses (261) 261
flow cytometry (259) 259
genetic aspects (257) 257
immunity (255) 255
cd4-positive t-lymphocytes - immunology (252) 252
pembrolizumab (251) 251
review (247) 247
ligands (246) 246
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4417) 4417
French (29) 29
German (28) 28
Japanese (20) 20
Polish (5) 5
Spanish (2) 2
Chinese (1) 1
Hebrew (1) 1
Hungarian (1) 1
Korean (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1749 - 1755
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Science, ISSN 0036-8075, 10/2018, Volume 362, Issue 6411, pp. 197 - 197
Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in... 
CELL LUNG-CANCER | MISMATCH-REPAIR DEFICIENCY | MUTATIONAL PROCESSES | METASTATIC MELANOMA | CTLA-4 BLOCKADE | MULTIDISCIPLINARY SCIENCES | COPY NUMBER | PROGRAMMED DEATH LIGAND-1 | SEQUENCING DATA | CLINICAL-RESPONSE | SOMATIC MUTATIONS | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Transcriptome | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Genetic Markers | Cell Cycle Checkpoints | Neoplasms - therapy | Neoplasms - genetics | Antineoplastic Agents, Immunological - therapeutic use | Immunotherapy | Inflammation - genetics | T-Lymphocytes - immunology | Tumor Burden - genetics | Biomarkers, Tumor - genetics | Mutation | Molecular Targeted Therapy - methods | Monoclonal antibodies | Genetic aspects | T cells | Biological markers | Gene expression | Cancer | Tumors | Apoptosis | Cell receptors | Physiological aspects | Diagnosis | Identification and classification | Methods | PD-1 protein | Clinical trials | Genomes | Biology | Lymphocytes T | Microsatellite instability | Data bases | Subgroups | Anticancer properties | Proteins | Cell activation | Pembrolizumab | Databases | Antigenicity | Lymphocytes | Bioindicators | Deoxyribonucleic acid--DNA | Medical research | Stability | Microsatellites | Mortality | Melanoma | Data processing | Inflammation | Patients | Immune checkpoint | Cell death | Correlation analysis | PD-L1 protein | Biomarkers | Ligands | Antitumor activity | Cutoffs | Solid tumors | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2189 - 2199
Journal Article
Journal Article
Nature, ISSN 0028-0836, 11/2017, Volume 551, Issue 7681, pp. 517 - 520
Checkpoint blockade immunotherapies enable the host immune system to recognize and destroy tumour cells(1). Their clinical activity has been correlated with... 
CELL LUNG-CANCER | CTLA-4 BLOCKADE | MELANOMA | THERAPY | LANDSCAPE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | RESISTANCE | CLINICAL-RESPONSE | REPERTOIRES | Humans | Lung Neoplasms - pathology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antigen Presentation | Melanoma - genetics | Immunotherapy | Cell Cycle Checkpoints - genetics | Cell Cycle Checkpoints - immunology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Antigens, Neoplasm - genetics | Antigens, Neoplasm - immunology | Carcinoma, Non-Small-Cell Lung - genetics | Lymphocyte Activation | CTLA-4 Antigen - genetics | Lung Neoplasms - therapy | Melanoma - pathology | CTLA-4 Antigen - immunology | Carcinoma, Non-Small-Cell Lung - immunology | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Models, Immunological | Melanoma - immunology | Survival Analysis | T-Lymphocytes - immunology | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Melanoma - therapy | Programmed Cell Death 1 Receptor - genetics | Cohort Studies | Evolution, Molecular | Antigens | Care and treatment | Patient outcomes | Models | Health aspects | Tumors | Medical research | Peptides | PD-1 protein | Lung cancer | Melanoma | Cytotoxicity | Lymphocytes T | Patients | Proteins | Cell recognition | CTLA-4 protein | Major histocompatibility complex | Immune checkpoint | Lymphocytes | Evolution | Mutation | Histocompatibility | Cancer | Immune system | Fitness | Index Medicus
Journal Article
Science, ISSN 0036-8075, 11/2015, Volume 350, Issue 6264, pp. 1079 - 1084
Journal Article
Science, ISSN 0036-8075, 10/2015, Volume 350, Issue 6257, pp. 207 - 211
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 11/2018, Volume 142, Issue 5, pp. 1403 - 1414
Journal Article